Spark Therapeutics (ONCE) in Focus: Stock Tumbles 5.7% – Tale of the Tape

On Mar 18, Spark Therapeutics announced financial results for 2014. Net loss for the year ended December 31, 2014 was $24.3 million, as compared with a net loss of $57.3 million for the period from March 13, 2013 (inception) to December 31, 2013.

Although this slump was obviously disappointing, the company’s current year consensus estimate trend has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for ONCE. So make sure to keep an eye on this stock going forward to see if Friday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

ONCE currently has a Zacks Rank #3 (Hold).

A better-ranked stock in the medical sector is Abaxis, Inc. (ABAX), which currently carries a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>